Tripeptide inhibitors of dengue and West Nile virus NS2B-NS3 protease

Antiviral Research

Volumn 92, Issue 1, 2011, Pages 96-101

  Schüller, Andreas ^a,e   Yin, Zheng ^b   Brian Chia, C S ^c   Doan, Danny N P ^a   Kim, Hyeong Kyu ^a   Shang, Luqing ^b   Loh, Teck Peng ^d   Hill, Jeffery ^c   Vasudevan, Subhash G ^a  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b NANKAI UNIVERSITY   (China)

^c Agency for Science   (Singapore)

^d NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^e PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Dengue virus; NS2B NS3 protease; Peptide inhibitor; West nile virus

Indexed keywords

ARGININE; LYSINE; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 2B; NONSTRUCTURAL PROTEIN 3; PROTEINASE INHIBITOR; TRIPEPTIDE ALDEHYDE INHIBITOR; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING SITE; CHEMICAL MODIFICATION; DENGUE; DENGUE VIRUS 2; DRUG STRUCTURE; DRUG SYNTHESIS; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; WEST NILE FLAVIVIRUS;

BINDING SITES; DENGUE VIRUS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; OLIGOPEPTIDES; PEPTIDE HYDROLASES; PROTEASE INHIBITORS; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL PROTEINS; WEST NILE VIRUS;

DENGUE VIRUS; DENGUE VIRUS TYPE 2; WEST NILE VIRUS;

EID: 80052859422     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.07.002     Document Type: Article

References (18)

1. Chandramouli S., Joseph J.S., Daudenarde S., Gatchalian J., Cornillez-Ty C., Kuhn P. Serotype-specific structural differences in the protease-cofactor complexes of the dengue virus family. J. Virol. 2010, 84:3059-3067.
2. Chappell K.J., Stoermer M.J., Fairlie D.P., Young P.R. Insights to substrate binding and processing by West Nile virus NS3 protease through combined modeling, protease mutagenesis, and kinetic studies. J. Biol. Chem. 2006, 281:38448-38458.
3. Erbel P., Schiering N., D'Arcy A., Renatus M., Kroemer M., Lim S.P., Yin Z., Keller T.H., Vasudevan S.G., Hommel U. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat. Struct. Mol. Biol. 2006, 13:372-373.
4. Hilal S.H., Karickhoff S.W., Carreira L.A. A rigorous test for SPARC's chemical reactivity models: estimation of more than 4300 ionization pKas. Quant. Struct.-Act. Rel. 1995, 14:348-355.
5. Knehans T., Schüller A., Doan D.N., Nacro K., Hill J., Güntert P., Madhusudhan M.S., Weil T., Vasudevan S.G. Structure-guided fragment-based in silico drug design of dengue protease inhibitors. J. Comput. Aided Mol. Des. 2011, 25:263-274.
6. Knox J.E., Ma N.L., Yin Z., Patel S.J., Wang W., Chan W., Ranga Rao K.R., Wang G., Ngew X., Patel V., Beer D., Lim S.P., Vasudevan S.G., Keller T.H. Peptide inhibitors of West Nile NS3 protease: SAR study of tetrapeptide aldehyde inhibitors. J. Med. Chem. 2006, 49:6585-6590.
7. Lescar J., Luo D., Xu T., Sampath A., Lim S.P., Canard B., Vasudevan S.G. Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from Dengue virus as a target. Antiviral Res. 2008, 80:94-101.
8. Li J., Lim S.P., Beer D., Patel V., Wen D., Tumanut C., Tully D.C., Williams J.A., Jiricek J., Priestle J.P., Harris J.L., Vasudevan S.G. Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries. J. Biol. Chem. 2005, 280:28766-28774.
9. Moulin A., Martinez J., Fehrentz J.-A. Synthesis of peptide aldehydes. J. Pept. Sci. 2007, 13:1-15.
10. Phong, W.Y., Moreland, N.J., Lim, S.P., Wen, D., Paradkar, P.N., Vasudevan, S.G., 2011. Dengue protease activity: the structural integrity and interaction of NS2B with NS3 protease and its potential as a drug target. Biosci. Rep. Epub ahead of print, PMID: 21329491. doi:10.1042/BSR20100142.
11. Petersen L.R., Marfin A.A. West Nile virus: a primer for the clinician. Ann. Intern. Med. 2002, 137:173-179.
12. Robin G., Chappell K., Stoermer M.J., Hu S., Young P.R., Fairlie D.P., Martin J.L. Structure of West Nile virus NS3 protease: ligand stabilization of the catalytic conformation. J. Mol. Biol. 2009, 385:1568-1577.
13. Stoermer M.J., Chappell K.J., Liebscher S., Jensen C.M., Gan C.H., Gupta P.K., Xu W., Young P.R., Fairlie D.P. Potent cationic inhibitors of West Nile virus NS2B/NS3 protease with serum stability, cell permeability and antiviral activity. J. Med. Chem. 2008, 51:5714-5721.
14. Su X., Ozawa K., Qi R., Vasudevan S.G., Lim S.P., Otting G. NMR analysis of the dynamic exchange of the NS2B cofactor between open and closed conformations of the West Nile virus NS2B-NS3 protease. PLoS Negl. Trop. Dis. 2009, 3:e561.
15. Wilder-Smith A., Ooi E.-E., Vasudevan S.G., Gubler D.J. Update on dengue: epidemiology, virus evolution, antiviral drugs, and vaccine development. Curr. Infect. Dis. Rep. 2010, 12:157-164.
16. Yin Z., Patel S.J., Wang W., Wang G., Chan W.L., Rao K.R., Alam J., Jeyaraj D.A., Ngew X., Patel V., Beer D., Lim S.P., Vasudevan S.G., Keller T.H. Peptide inhibitors of dengue virus NS3 protease. Part 1: warhead. Bioorg. Med. Chem. Lett 2006, 16:36-39.
17. Yin Z., Patel S.J., Wang W., Chan W., Ranga Rao K., Wang G., Ngew X., Patel V., Beer D., Knox J.E., Ma N.L., Ehrhardt C., Lim S.P., Vasudevan S.G., Keller T.H. Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors. Bioorg. Med. Chem. Lett. 2006, 16:40-43.
18. Yusof R., Clum S., Wetzel M., Krishna Murthy H.M., Padmanabhan R. Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro. J. Biol. Chem. 2000, 275:9963-9969.